Company Website. Company Presentation.
And as I mentioned above, INM has several potential breakout catalysts to familiarize yourself with ASAP. Here they are:
No. 1 INM Potential Catalyst - A Stunningly Low Float Could Lead To Extreme Volatility
According to the Yahoo Finance website, INM has a low float.
The website reports this profile to have approximately 3.31Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available, the potential for volatility rises (when considering the size of a profile's float).
Could more 2023 positive company news help provide a near term spark?
No. 2 INM Potential Catalyst - Key Update Details Regarding Company's Strong Pipeline Of Programs
InMed Reports Second Quarter Fiscal 2023 Fi-nan-cial Results and Provides Business Update
- Closed calendar year 2022 with strong cash position of $11.5Mn
- Approaches completion of enrollment for Ph 2 clinical trial in EB
- Advances research using rare cann-a-binoids in treating glaucoma and neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), ..., today announced fi-nan-cial results for the second quarter of fiscal year 2023 which ended December 31, 2022.
“This period was another strong operational quarter for the Company as we advanced our pharmaceutical programs, including the launch of INM-900 series compounds for the evaluation of neurodegenerative diseases. We are currently approaching the end of enrollment in our Ph 2 clinical trial in Epidermolysis Bullosa (“EB”). As we move into calendar 2023, we have a strong pipeline of programs at various stages of development,” said Eric A. Adams, President and CEO of InMed. “Fiscal Q2 saw significant cost savings across the different business segments resulting in a reduced cash burn. In addition, our strong cash position of over $11Mn enables us to pursue several material milestones throughout calendar 2023.”
Pharmaceutical Development Programs
INM-755 – Phase 2 Clinical Trial in EB
To date, the Ph 2 clinical trial has enrolled 17 patients of its targeted 20 patients. Several additional prospective patients have been identified for screening at the clinical sites and enrollment is expected to complete at the end of March 2023, with initial read out expected in early calendar 3Q 2023.
INM-088 – Glaucoma Program
The Company continues to conduct the required IND enabling preclinical testing and has planned GLP toxicology studies in mid-2023. Human clinical trials remain on track to commence in calendar 2024.
INM-900 – Neurodegenerative Diseases Program
Two cann-a-binoid analogs are being assessed in in vivo models of neurodegenerative diseases and the Company expects these studies to be completed and a candidate selected for further development in calendar 2Q 2023. Our research demonstrated the neuroprotective effects of specific cann-a-binoid analogs and their potential to improve neuronal function.
BayMedica Commercial Business
BayMedica continues to be a leading producer of cann-a-bichromene (CBC) with increased revenue in the last two quarters, including a 46% quarter over quarter increase in fiscal 2Q 2023. Management continues to evaluate strategic options and long-term supply agreements for this business segment.
Read the full article here.
No. 3 INM Potential Catalyst - Published Peer Review Study Demonstrate The Anti-inflammatory Effects Of Rare Cann-a-binoids
InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cann-a-binoids in Skin Conditions
Supports the therapeutic potential of rare cann-a-binoids in inflammatory skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne
Further demonstrates the anti-inflammatory effects of CBC, TH-CV, CBG and CB-GA
Details possible mechanisms of action on how rare cann-a-binoids can interact with specific skin-related endocann-a-binoid receptors
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), ..., today announced that a peer-reviewed scientific study entitled "Rare phytocann-a-binoids exert anti-inflammatory effects on human keratinocytes via the endocann-a-binoid system and MAPK signalling pathway" has been published in the International Journal of Molecular Sciences. This is the second such Company-sponsored study to demonstrate the anti-inflammatory effects of rare cann-a-binoids and their potential application for the treatment of skin conditions such as atopic dermatitis, psoriasis, pruritus, and acne.
The study, conducted in collaboration with Dr. Mauro Maccarrone at the Università degli Studi dell'Aquila, investigates the anti-inflammatory effects of the rare cann-a-binoids, canna-bichromene (CBC), Δ-9-tetra-hydro-canna-bivarin (TH-CV), canna-bigerol (CBG) and canna-bigerolic acid (CB-GA) on inflamed human keratinocytes (HaCaT cells) and elucidates the potential mechanism of action associated with these compounds in the skin.
Results demonstrate these rare cann-a-binoids significantly blocked inflammation by reducing the release of tested pro-inflammatory interleukins, including IL-1β, IL-8, IL-12, IL-31, IL-10 and tumor necrosis factor (TNF-β). Results showed that TH-CV and CB-GA act synergistically with the endocann-a-binoid system elements to activate anti-inflammatory effects. This demonstration of the mechanism of action opens new perspectives for possible treatments of inflammation-related skin conditions.
"This study provides further evidence of the ability of rare cann-a-binoids to exert anti-inflammatory effects in human keratinocytes through modifications of the endocann-a-binoid system and MAPK signalling," said InMed's scientific advisor, Dr. Mauro Maccarrone, Professor and Chair of Biochemistry at the Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy. "Results from this study demonstrate important mechanisms of biological effects of rare cann-a-binoids and support the therapeutic potential of TH-CV and CB-GA on inflammation-related skin conditions."
"Research into the biological activity of the rare cann-a-binoids has been limited to date and InMed continues to support this foundational research to further understand the pharmacological properties of these rare cann-a-binoids," said Dr. Eric Hsu, Senior VP, Preclinical Research and Development. "As we continue to build our pipeline of rare cann-a-binoid and cann-a-binoid analog therapeutics, evidence demonstrating the specific biological activity will be key in the selection and advancement of our programs."
Read the full article here.
No. 4 INM Potential Catalyst - Neurodegenerative Disease Program Advances With Help From NSERC Grant Funding
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
- Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
- Identified two lead cann-a-binoid analog compounds for in vivo studies
- NSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar from University of British Columbia (UBC)
VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), ..., today announces the launch of its neurodegenerative disease program (INM-900 series), which will be investigating the effects of cann-a-binoid analogs in diseases such as Alzheimer’s, Huntington’s and Parkinson’s.
In research conducted to date, InMed has identified two cann-a-binoid analogs demonstrating promising effects related to the treatment of neurodegenerative diseases, warranting further investigation in in vivo studies. InMed will be conducting studies using in vivo models in neurodegenerative disease to select the most appropriate candidate for clinical studies. Early preclinical efficacy readout is expected in 2Q 2023.
In addition, Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences at UBC has been awarded an Alliance grant from NSERC, with InMed as the named industry partner. The funding will support the research and development studies of InMed’s cann-a-binoid pharmaceutical candidates, investigating their potential therapeutic effects in neurodegenerative diseases. The collaboration project is entitled “Pharmacological characterization of phytocann-a-binoids and the endocann-a-binoid system.”
InMed's Senior Vice President of Preclinical Research & Development, Eric Hsu, Ph.D., commented, "We are pleased that our efforts have led to the identification of two cann-a-binoid analog candidates to advance to in vivo studies. Our team will continue this important research in neurodegenerative diseases under the NSERC Alliance grant. Our early studies are showing promising neuroprotective effects as well as neurite outgrowth, signifying the potential to enhance neuronal function that may be important in the treatment of neurodegenerative diseases. This program, in conjunction with the work we are doing within glaucoma, increases our focus on, and expands our pipeline within, the neuroprotection space.”
In December 2021, InMed filed an international patent application demonstrating neuroprotection and enhanced neuronal function using rare cann-a-binoids and analogs for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease and others. The patent specifies such compounds that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in a population of affected neurons.
Read the full article here.
No. 5 INM Potential Catalyst - Could Oversold Leaning Technicals Signal Significant Bounce/Reversal Potential?
As of 2:00PM EST Wednesday, Barchart was reporting this profile to have several oversold leaning technicals.
These technicals could be signaling a healthy reversal could be approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Now, here are some key technicals (as of 2:00PM EST Wednesday) that could signal INM to be leaning oversold and on the verge of a potential reversal.
- 9-Day Relative Strength Index: 32.53%
- 14-Day Relative Strength Index: 33.56%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 26.92%
- 14-Day Williams %R: 73.08%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
INM Recap - Multiple Potential Catalysts Could Lead To A Breakout Spark
No. 1 - A Stunningly Low Float Could Lead To Extreme Volatility
No. 2 - Key Update Details Regarding Company's Strong Pipeline Of Programs
No. 3 - Published Peer Review Study Demonstrate The Anti-inflammatory Effects Of Rare Cann-a-binoids
No. 4 - Neurodegenerative Disease Program Advances With Help From NSERC Grant Funding
No. 5 - Could Oversold Leaning Technicals Signal Significant Bounce/Reversal Potential?
Coverage is officially reinitiated on INM. When time permits, do this: